Trelleborg Sealing Solutions Leverages LSR Technology for Transdermal and Subcutaneous Delivery Systems
Device manufacturers are investing in R&D and design strategies to support the transdermal drug delivery industry, valued at $13.5 billion in 2013 and expected to reach $21.7 billion by 2018 according to the Micromarket Monitor.
With the sophisticated developments in microneedle patches, injectors and pre-filled syringes come increasing opportunities for using Liquid Silicone Rubber (LSR) technology, a specialty of Trelleborg Sealing Solutions, to enhance the performance of these devices, ensure biocompatibility, meet industry regulations and facilitate the high volume manufacturing that is now required for such devices.
Luis Tissone, Life Sciences Director for Trelleborg Sealing Solutions in the Americas, says: “We are excited at the opportunity to draw from decades of LSR technology experience and collaborate with engineering visionaries interested in advancing transdermal and subcutaneous drug delivery systems. We excel in solving product design challenges through shoulder-to-shoulder engineering and leveraging our sealing experts globally.
“Engineering teams have started to recognize the value LSR technology can bring to the drug delivery market, in addition to other medical device areas within dialysis, respiratory, surgical, prosthetics and biopharma, just to name a few.”
At MD&M, Trelleborg welcomes attendees to visit booth 1527 where it will share its expertise in LSR technology with the medical device and life sciences community. In addition, Trelleborg Sealing Solutions will showcase an array of the newest seals, LSR and rubber molded components, silicone and plastic tubing, O-Rings, gaskets and bearings used in medical devices and biopharma.
Visit www.trelleborg-lifesciences.com for more information on Trelleborg Sealing Solutions' offerings for the life sciences market.